Biomx INC

BiomX Inc. has amended a promissory note with Water IO Ltd., extending the maturity date and issuing restricted stock as consideration for accrued interest and payment delay.

BiomX Inc. has cancelled 1,013,637 restricted shares to regain compliance with NYSE American listing rules pending shareholder approval of a prior acquisition.

BiomX Inc. has dismissed Kesselman & Kesselman (PwC) as its independent auditor and engaged Barzily & Co. for the fiscal year ending December 31, 2026.

BiomX Inc. shareholders elected a director and approved an increase in shares for the 2026 Equity Incentive Plan.

BiomX Inc. announced an updated informational presentation detailing its strategic transition to a defense and security technology holding company, focusing on threat identification, analysis, and response.

BiomX Inc. has received approval from the NYSE American for a compliance plan to address stockholders' equity deficiencies, extending its listing deadline to September 25, 2027.

BiomX Inc. reports Q1 2026 results following a strategic pivot from clinical-stage biopharma to defense and security technology.

BiomX reported a significant increase in net loss for Q3 2025, alongside a going concern warning, while its lead cystic fibrosis program faced an FDA clinical hold.

BiomX Inc. reported increased net losses and a significant decline in cash, raising substantial doubt about its ability to continue as a going concern, despite positive clinical trial results for its lead programs.

BiomX Inc. reports its financial results for the quarter ended March 31, 2025, highlighting progress in its clinical programs and recent financing activities.

BiomX Inc. reports a net loss of $9.6 million for the third quarter of 2024, alongside updates on clinical trial progress and a reverse stock split.

BiomX Inc. reported its financial results for the second quarter of 2024, showcasing advancements in its clinical programs and the impact of the Adaptive Phage Therapeutics acquisition.

BiomX Inc. filed an amendment to its 2025 Annual Report, detailing a complete turnover of its executive leadership team and significant changes to its Board of Directors.

BiomX Inc. reported significant losses and a going concern warning, alongside a strategic pivot, workforce reduction, and a new $3.0 million capital raise contingent on stockholder approval.

BiomX Inc. files its 2024 10-K, detailing clinical advancements in phage therapy for cystic fibrosis and diabetic foot osteomyelitis, alongside its financial status and future outlook.

BiomX Inc. outlines the terms of its registered securities, including common stock, units, and warrants, all listed on the NYSE American Stock Market.

BiomX Inc. director and 10% owner Reuven Yeganeh reported converting preferred stock into common shares and subsequently selling common stock and warrants in private transactions.

James E. Flynn, a director by deputization of BiomX Inc., reports the acquisition of warrants exercisable for 1,611,864 shares of common stock after stockholder approval was obtained.

Gregory Louis Merril, a director of BiomX Inc., filed an amended Form 4 to correct an administrative error in the reporting of derivative securities acquired.

Merav Bassan, Chief Development Officer of BiomX Inc., reports acquisition of restricted stock units and stock options in an amended SEC filing.

BiomX Inc. CEO Jonathan Solomon received 126,748 Restricted Stock Units and options to purchase 380,500 shares of common stock, according to a Form 4/A filing.

A BiomX Inc. director, Jesse Goodman, filed an amended Form 4 to correct an administrative error in the reporting of derivative securities acquired.

BiomX Inc. has issued a proxy statement for its 2026 Annual Meeting to elect a director and approve a significant increase in shares reserved for its equity incentive plan.

BiomX Inc. is convening an Extraordinary Special Meeting to approve a new 2026 Equity Incentive Plan, crucial for talent retention amidst recent leadership changes.

BIOMX INC. has filed definitive additional proxy materials with the U.S. Securities and Exchange Commission.

BiomX Inc. will hold its 2025 Annual Meeting to elect directors, ratify auditors, and seek authorization for a reverse stock split to boost share price and facilitate capital raising.

BiomX Inc. has filed a supplement to its definitive proxy statement to correct errors in the beneficial ownership table in advance of its Special Meeting of Stockholders on April 21, 2025.

BiomX Inc. issues a supplement to its definitive proxy statement to correct errors regarding stockholder voting eligibility and the number of Series X Preferred Stock shares outstanding.

BiomX Inc. has filed a registration statement for the resale of up to 7,163,000 shares of its common stock by selling stockholders, following a significant business transformation.

BiomX Inc. has filed a registration statement for the resale of up to 15,200,780 shares of common stock issuable upon the exercise of pre-funded, common, and new warrants held by selling securityholders.

Deerfield Management and affiliated funds have reduced their beneficial ownership in BiomX Inc. to below 5%, triggering this Schedule 13D amendment.

Deerfield Management entities reported recent warrant exercises, preferred stock conversions, and open market sales of BiomX Inc. common stock.

Deerfield Management reports a change in its percentage of beneficial ownership in BiomX Inc. due to an increase in the company's total outstanding shares.

An amendment to a Schedule 13D filing reveals that Menachem Shalom, along with affiliated entities, now beneficially owns 20.4% of BiomX Inc. common stock following a business acquisition.

BiomX Inc. has acquired Zorro Net Ltd., a visual AI and computer vision technology firm, from Water IO Ltd. for 1.3 million shares of BiomX common stock and a $1.25 million promissory note.

Deerfield Management's partner, Jonathan Leff, has resigned from the board of directors of BiomX Inc., as Deerfield entities maintain a 9.99% beneficial ownership stake.

A group of investment entities led by Rodney Hodges has disclosed a 5.2% beneficial ownership stake in BiomX Inc.

Nantahala Capital Management, LLC and its managing members reported a 9.99% beneficial ownership stake in BiomX Inc. as of December 31, 2025.

AIGH Capital Management LLC and Orin Hirschman have filed an amended Schedule 13G, reporting a 0.1% beneficial ownership stake in BioMX Inc. as of December 31, 2025.

Morgan Stanley and its subsidiary have reported ceasing beneficial ownership of more than five percent of BiomX Inc.'s common stock.

Morgan Stanley and its subsidiary have reported a 7.1% beneficial ownership stake in BiomX Inc.'s common stock, held in the ordinary course of business.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 9.99% in BiomX Inc.'s common stock as of March 31, 2025.